High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
928.03M
+39.51%
0.169
-212.5%
919.85M
+48.27%
0.244
+74.57%
961.44M
+46.83%
0.287
+51.26%
Estimates Revision
The market is revising Downward the revenue expectations for Astrana Health, Inc. (ASTH) for FY2025, with the revenue forecasts being adjusted by -1.23% over the past three months. During the same period, the stock price has changed by -23.27%.
Revenue Estimates for FY2025
Revise Downward
-1.23%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-38.58%
In Past 3 Month
Stock Price
Go Down
-23.27%
In Past 3 Month
6 Analyst Rating
Wall Street analysts forecast ASTH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASTH is 32.67 USD with a low forecast of 26.00 USD and a high forecast of 37.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 22.790
Low
26.00
Averages
32.67
High
37.00
Current: 22.790
Low
26.00
Averages
32.67
High
37.00
Jefferies
Buy
downgrade
$44 -> $37
2025-11-25
Reason
Jefferies
Price Target
$44 -> $37
2025-11-25
downgrade
Buy
Reason
Jefferies lowered the firm's price target on Astrana Health to $37 from $44 and keeps a Buy rating on the shares. The bar for fiscal 2026 EBITDA is low and implies little confidence in the full-risk contract conversion delays that management is assuming will be effective in the first quarter of 2026, the analyst tells investors in a research note. Jefferies believes potential upside for Astrana from Medicare Advantage in 2026 is underappreciated, but thinks proof-points on 1H26 trends are needed to restore confidence.
Barclays
Andrew Mok
Equal Weight
downgrade
$36 -> $26
2025-11-24
Reason
Barclays
Andrew Mok
Price Target
$36 -> $26
2025-11-24
downgrade
Equal Weight
Reason
Barclays analyst Andrew Mok lowered the firm's price target on Astrana Health to $26 from $36 and keeps an Equal Weight rating on the shares post the Q3 report. The company's contracting trade-off is understandable, but introduces an element of risk to its EBITDA targets in 2026 and 2027, the analyst tells investors in a research note.
TD Cowen
Ryan Langston
Buy
downgrade
$40 -> $35
2025-11-10
Reason
TD Cowen
Ryan Langston
Price Target
$40 -> $35
2025-11-10
downgrade
Buy
Reason
TD Cowen analyst Ryan Langston lowered the firm's price target on Astrana Health to $35 from $40 and keeps a Buy rating on the shares. The firm said its forward estimates reflecttheir cautious outlook on Medicaid and the VBC environment.
BTIG
David Larsen
Buy
downgrade
$70 -> $50
2025-07-30
Reason
BTIG
David Larsen
Price Target
$70 -> $50
2025-07-30
downgrade
Buy
Reason
BTIG analyst David Larsen lowered the firm's price target on Astrana Health to $50 from $70 and keeps a Buy rating on the shares. The company could face headwinds from higher cost trends, though it has already provided favorable comments around Q2 results, the analyst tells investors in a research note. There have been some worries about home-health reimbursement, but the specialty medical trend and home-health and rehab volumes will likely far offset these worries, the firm added.
Barclays
Andrew Mok
Hold
Initiates
$36
2025-04-01
Reason
Barclays
Andrew Mok
Price Target
$36
2025-04-01
Initiates
Hold
Reason
Barclays initiated coverage of Astrana Health with an Equal Weight rating and $36 price target. The company is well positioned to capture improving rates in the government sector, but the scale and complexity of the pending Prospect deal tempers excitement, the analyst tells investors in a research note. The firm believes the near-term execution risks are real given the scale. As such, it comes out on the sidelines.
Truist Securities
Jailendra Singh
Strong Buy
Maintains
$50 → $46
2025-03-18
Reason
Truist Securities
Jailendra Singh
Price Target
$50 → $46
2025-03-18
Maintains
Strong Buy
Reason
Truist analyst Jailendra Singh lowered the firm's price target on Astrana Health to $46 from $50 and keeps a Buy rating on the shares. The firm is updating its model to reflect the company's Q4 earnings release and 2025 outlook, the analyst tells investors in a research note. Truist adds that its valuation represents a slight premium to Astrana's next-12-months enterprise value to EBITDA average multiple over the last year and gives credit to its recent history of outperformance relative to the value-based care industry as a whole.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Astrana Health Inc (ASTH.O) is 21.75, compared to its 5-year average forward P/E of 37.00. For a more detailed relative valuation and DCF analysis to assess Astrana Health Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
37.00
Current PE
21.75
Overvalued PE
56.44
Undervalued PE
17.56
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
11.58
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
17.97
Undervalued EV/EBITDA
5.19
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
1.35
Current PS
0.00
Overvalued PS
2.39
Undervalued PS
0.30
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
ASTH News & Events
Events Timeline
(ET)
2025-11-06
16:26:22
Astrana Health Adjusts 2025 Revenue Forecast to $2.5B-$2.7B, Down from $3.1B-$3.18B
2025-11-06
16:25:21
Astrana Health announces Q3 EPS of 1 cent compared to 33 cents in the previous year.
2025-08-07 (ET)
2025-08-07
16:49:57
Astrana Health sees 2025 revenue $3.1B-$3.3B, consensus $3.18B
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/benzinga.png)
Preview
4.0
11-26BenzingaJefferies Keeps Buy Rating on Astrana Health, Reduces Price Target to $37
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/64a4c1e1ccaa088a11fe5db11483a4dcf64d70b750efad0e3ff530f8296fbba1.jpg)
Preview
8.0
11-26NASDAQ.COMSignificant Options Trading on Tuesday: AMZN, ASTH, WDAY
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/db582880a1130f467700b2c991168d80905271ba2880609293d50ca7e05d726e.jpg)
Preview
8.0
11-24NASDAQ.COMNoteworthy ASTH Put and Call Options Set for January 2026
Sign Up For More News
People Also Watch
FAQ
What is Astrana Health Inc (ASTH) stock price today?
What is Astrana Health Inc (ASTH)'s business?
What is the price predicton of ASTH Stock?
What is Astrana Health Inc (ASTH)'s revenue for the last quarter?
What is Astrana Health Inc (ASTH)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Astrana Health Inc (ASTH)'s fundamentals?
How many employees does Astrana Health Inc (ASTH). have?